Compare MCFT & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCFT | AVXL |
|---|---|---|
| Founded | 1968 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 379.3M | 388.7M |
| IPO Year | 2015 | 2013 |
| Metric | MCFT | AVXL |
|---|---|---|
| Price | $19.90 | $4.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $22.25 | $22.00 |
| AVG Volume (30 Days) | 163.2K | ★ 1.1M |
| Earning Date | 05-04-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $284,203,000.00 | N/A |
| Revenue This Year | $9.18 | N/A |
| Revenue Next Year | $8.23 | N/A |
| P/E Ratio | $54.17 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.42 | $2.86 |
| 52 Week High | $26.49 | $13.99 |
| Indicator | MCFT | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 31.22 | 56.73 |
| Support Level | $18.77 | $3.60 |
| Resistance Level | $21.20 | $4.88 |
| Average True Range (ATR) | 0.84 | 0.26 |
| MACD | -0.43 | 0.08 |
| Stochastic Oscillator | 5.83 | 61.03 |
MasterCraft Boat Holdings Inc designs, manufactures, and markets performance sport boats and outboard boats. The company is based in the United States and operates in three brand-specific segments. The MasterCraft segment generates the majority of the company's revenue and includes inboard boats for water skiing, wakeboarding, and wake surfing. The Pontoon segment produces pontoon boats at its Owosso, Michigan facility. Pontoon boats are used for general recreational boating. The Aviara segment produces luxury day boats at its Merritt Island, Florida facility. Aviara boats are used for general recreational boating.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.